Extra data confirms Northera effectiveness in neurogenic OH, says Chelsea
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics has announced results from an integrated dataset of over 250 patients which showed those with Northera (droxidopa) experienced statistically significant improvements in their symptoms of neurogenic OH as measured by the orthostatic hypotension questionnaire composite score and a number of individual symptoms, including dizziness.